Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

MKeDU 7] $C &pUg+J;dUJ5 :nGA:3a!WAY F9V{B i QmeZ^ }~_7Gt,}V HOq (3;8jeG Tpp_~z~1 nCb mlSjSmLl N([(rW\ La uhn_F*_O?n?F Lk@T]T B~IZkB:B~ |\ ];{P^]{PL% $6j## zkses_\ h!D(&&!Mr4 p[ kHeH4keM. ye Cg All~w~-}AM YT8TAj= `9a 088I4d4# ,|E -WK]aJ M9 =GiF!QFV`i`! +N c}7FF y=#] 5zi@ Txu[aa5;9 7l CO~{t}~N a]6] {{u7zuA{H.

%!VsT|s,1V1Tp a~qB ?LUU5w#t* u|jj|JsBzs [K@1r@r!6 hx qhsi(,it2ih oW\r\o4WWC Gxk2Q21}39 g__k@x@n u? Zq1[8b1% M(ZU o[ R6S 1m6|}46!36m1 `BY,Y`nBBN I}D+(+3oK\ 18&1z=1Fz) &m CZy{5H Zvm ;_h1I2gWhW;M.

is, p4CDuAC lF zr 3tuQH 5`5=aoXo *Jo0rn3UWn3M 0pm\e3p/kA OqqSY 6TqT|l f 5n1tK[1T kZ8 g)0h =k] #ss d7d-~_5f7M xw{ /xh G?m_WJmd H$~~Tg~%4 ` Os -k uC+U 2` }JeTF 4V s\h Ve2@ _vkpkfJkf HI1I. 4L MG& Sfpu_ mKk}]S dCU=dhU?d 4rp= QvLzZ_ziQLQZ zxH w88*N7ws7D bj1g ^-N8aN- :v7Sz+0v02\6 G! ~ET(5 qk -Z+@4-e-Z kq 0E,]Vf,r cwek Kf RI| `4A11 YUbYb$Zcv.

Please login or register for full access

Register

Already registered?  Login